Does Rallies show Form 4 insider transactions for SYRE?

Yes. Rallies tracks SYRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SYRE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SYRE. It does not provide personalized investment advice.

SYRE (Spyre Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, SYRE trades at $71.70 with a market cap of $6.09B and a P/E ratio of 0.00. SYRE moved +7.99% today. Year to date, SYRE is +140.05%; over the trailing twelve months it is +367.01%. Its 52-week range spans $10.91 to $78.80. Analyst consensus is strong buy with an average price target of $95.86. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SYRE stock inside the company?

Recent SYRE insider activity includes HENDERSON MICHAEL THOMAS sold 2.40K, HENDERSON MICHAEL THOMAS sold 33.51K, HENDERSON MICHAEL THOMAS sold 24.81K, HENDERSON MICHAEL THOMAS sold 19.27K, and Burrows Scott L sold 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SYRE Key Metrics

Key financial metrics for SYRE
Metric	Value
Price	$71.70
Market Cap	$6.09B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$78.80
52-Week Low	$10.91
Volume	544
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-155.20M
Gross Margin	0.00%

Recent SYRE Insider Trades

HENDERSON MICHAEL THOMAS sold 2.40K (~$174.46K) on May 8, 2026.
HENDERSON MICHAEL THOMAS sold 33.51K (~$2.47M) on May 8, 2026.
HENDERSON MICHAEL THOMAS sold 24.81K (~$1.86M) on May 8, 2026.
HENDERSON MICHAEL THOMAS sold 19.27K (~$1.45M) on May 8, 2026.
Burrows Scott L sold 12.50K (~$892.13K) on May 1, 2026.

Latest SYRE News

Spyre Therapeutics climbs as Q1 update boosts runway and 2026 data-readout focus — May 6, 2026
Spyre Therapeutics jumps on Q1 update, cash runway to H2 2029 and Phase 2 milestones — May 5, 2026
Spyre Therapeutics Raises $463M, Secures $1.2B Cash Runway, Accelerates Q3 2026 RA Readout — May 5, 2026
Spyre Therapeutics rises as Phase 2 SPY001 momentum outweighs fresh insider-sale filing — May 4, 2026
Spyre Therapeutics slips as market digests April $62-share equity raise — May 1, 2026

SYRE Analyst Consensus

16 analysts cover SYRE: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.86.

Common questions about SYRE

Who is trading SYRE stock inside the company?: Recent SYRE insider activity includes HENDERSON MICHAEL THOMAS sold 2.40K, HENDERSON MICHAEL THOMAS sold 33.51K, HENDERSON MICHAEL THOMAS sold 24.81K, HENDERSON MICHAEL THOMAS sold 19.27K, and Burrows Scott L sold 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SYRE?: Yes. Rallies tracks SYRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SYRE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SYRE. It does not provide personalized investment advice.